BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity
Botanical Synthesis™-developed asset has now completed development, commercial-scale manufacturing and the applicable self-affirmed GRAS process and is ready for production at BioHarvest’s GMP facility. Milestone demonstrates BioHarvest’s ability to create proprietary plant-derived assets and advance them from plant-cell development through industrial manufacturing and commercialization. High-potency proprietary olive-derived Verbascoside composition demonstrates promising dose-dependent preclinical activity across
